Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person midostaurin [cytosol]

Class:IdChemicalDrug:2038921
_displayNamemidostaurin [cytosol]
_timestamp2019-12-03 01:11:46
compartment[Compartment:70101] cytosol
created[InstanceEdit:2038920] Rothfels, K, 2012-01-10
crossReference[DatabaseIdentifier:9627977] ChEBI:63452
disease[Disease:1500689] cancer
literatureReference[LiteratureReference:2077411] FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
[LiteratureReference:1679952] PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder
[LiteratureReference:1606521] The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
modified[InstanceEdit:2067723] Rothfels, K, 2012-01-25
[InstanceEdit:2077554] Rothfels, K, 2012-01-27
[InstanceEdit:9603969] Rothfels, Karen, 2018-03-28
[InstanceEdit:9608018] Weiser, JD
[InstanceEdit:9616752] Shorser, Solomon, 2018-08-13
[InstanceEdit:9619953] Wu, G, 2018-09-19
[InstanceEdit:9627975] Wu, G, 2018-11-05
[InstanceEdit:9631716] Wu, G, 2018-12-12
[InstanceEdit:9669666] Rothfels, Karen, 2019-12-03
namemidostaurin
PKC412
referenceEntity[ReferenceTherapeutic:9603942] midostaurin [Guide to Pharmacology:5702]
stableIdentifier[StableIdentifier:2298130] R-ALL-2038921.3
summation[Summation:2077547] PKC412 is a multi-tyrosine kinase inhibitor that has been sh...
(hasMember)[DefinedSet:2045079] Tyrosine kinase inhibitors of FGFR1 fusion mutants [cytosol]
[DefinedSet:2077416] Tyrosine kinase inhibitors of FGFR3 mutants [cytosol]
[DefinedSet:9669710] type I KIT binding TKIs [cytosol]
[DefinedSet:9695790] type I FLT3-binding TKIs [cytosol]
(input)[FailedReaction:9702601] midostaurin-resistant FLT3 mutants don't bind midostaurin [Homo sapiens]
(updatedInstance)[_UpdateTracker:9901016] Update Tracker - [ChemicalDrug:2038921] midostaurin [cytosol] - v72:[modifyName]
[Change default viewing format]
No pathways have been reviewed or authored by midostaurin [cytosol] (2038921)
Follow Reactome